REL-(1R,4S,4AR,5S,8R,8AS)-5,6,7,8,9,9-HEXACHLORO-1,4,4A,5,8,8A-HEXAHYDRO-1,4


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FYISZJZMDZHFEQ-AXEYQCJTSA-N
Smiles	ClC1=C(Cl)[C@@]2(Cl)[C@H]3[C@@H]4C[C@@H](N=N4)[C@H]3[C@]1(Cl)C2(Cl)Cl
InChI	InChI=1S/C10H6Cl6N2/c11-6-7(12)9(14)5-3-1-2(17-18-3)4(5)8(6,13)10(9,15)16/h2-5H,1H2/t2-,3+,4-,5+,8-,9+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H6Cl6N2
Molecular Weight	366.89
AlogP	3.75
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	0.0
Polar Surface Area	24.72
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	18.0

Assay Description	Organism	Bioactivity
Competitive inhibition of [35S]TBPS binding to gamma-aminobutyric acid type-A receptor in Rattus norvegicus (rat) brain membranes at 50 nM incubated for 90 min by Scatchard plot	Rattus norvegicus	None
Insecticidal activity against WHO susceptible Musca domestica (house fly) assessed as compound level causing mortality per fly applied through topical application	Musca domestica	2.8 ng
Displacement of [35S]TBPS from gamma-aminobutyric acid type-A receptor in Rattus norvegicus (rat) brain membranes incubated for 90 min by liquid scintillation counting method	Rattus norvegicus	48.4 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2268920
PubChem	76312332

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).